SARS-CoV-2 mRNA Vaccine Booster in Ofatumumab-Treated Patients With Relapsing MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Vaccines
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
Vaccines (Basel) 2023 May 13;11(5)978, T Ziemssen, E Schlegel, M Groth, B Ettle, T BoppFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.